Get the Stockscreener App
1.09
21.10%
0.1899
Inovio Pharmaceuticals Inc stock is traded at $1.09, with a volume of 12.13M.
It is up +21.10% in the last 24 hours and down -6.03% over the past month.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
See More
Previous Close:
$0.9001
Open:
$0.9295
24h Volume:
12.13M
Relative Volume:
4.03
Market Cap:
$112.63M
Revenue:
$65,300
Net Income/Loss:
$-84.93M
P/E Ratio:
-0.6382
EPS:
-1.708
Net Cash Flow:
$-83.57M
1W Performance:
+63.17%
1M Performance:
-6.03%
6M Performance:
-32.30%
1Y Performance:
-32.72%
1-Day Range:
$0.8978
$1.10
1-Week Range:
$0.6596
$1.10
52-Week Range:
$0.5632
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.09 | 79.56M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - marketwatch.com
HC Wainwright Issues Negative Estimate for INO Earnings - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to Strong-Buy at Zacks Research - MarketBeat
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
INO Upgraded by Jefferies -- Price Target Raised to $3.00 - GuruFocus
Piper Sandler Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
H.C. Wainwright reiterates Neutral on Inovio stock, $2.50 target By Investing.com - Investing.com Canada
Inovio Q2 2026 slides: INO-3107 on track for Oct FDA decision - Investing.com Nigeria
Jefferies upgrades Inovio stock rating on FDA review progress By Investing.com - Investing.com Canada
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO): What Does the Latest Update Mean for Regulatory Progress? - Kalkine Media
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ... - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlig - GuruFocus
Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Inovio Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:INO) 2026-08-12 - Seeking Alpha
Inovio (INO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Inovio Pharmaceuticals, Inc. (INO) stock price, news, quote and history - Yahoo Finance UK
Inovio Q2 EPS $(0.07) beats $(0.22) estimate; loss narrows 74% - scanx.trade
Inovio Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Earnings call transcript: Inovio narrows Q2 2026 loss as INO-3107 nears FDA date - Investing.com
Inovio Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Inovio: Q2 Earnings Snapshot - marketscreener.com
BRIEF-Inovio Pharmaceuticals Q2 Operating Expenses USD 18.6 Million - TradingView
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights - PR Newswire
Adage Capital (INO) discloses 3.43M Inovio shares via warrants in 13G/A - Stock Titan
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - AOL.com
Inovio Pharmaceuticals (NASDAQ:INO): What Could Today’s pipeline focus and funding discipline Update Reveal? - Kalkine Media
Inovio Pharmaceuticals Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
RA Capital reports 10.67M-share Inovio (NASDAQ: INO) stake capped at 9.99% - Stock Titan
Inovio Pharmaceuticals, Inc. Share Price Live Today – NASDAQ:INO Stock Price, Chart, News, History - Upstox
Inovio Pharmaceuticals (INO.US) will release its earnings report after market close on August 12. - Moomoo
FMR LLC (INO) discloses 8.45M Inovio shares, including major fund holder - Stock Titan
Inovio Pharmaceuticals (INO) Projected to Release Earnings on Wednesday - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - marketwatch.com
INOVIO to Report Second Quarter Financial Results on August 12, 2026 - Moomoo
INO Reiterates by Piper Sandler -- Price Target Lowers to $4.00 - GuruFocus
Piper Sandler Reiterates "Overweight" Rating for Inovio Pharmaceuticals (NASDAQ:INO) - MarketBeat
Inovio Pharmaceuticals Inc : Piper Sandler Cu - moomoo.com
Inovio proposes underwritten public offering of common stock, warrants - Bitget
Vanguard Capital Management (INO) discloses 5.05% beneficial stake in Inovio stock - Stock Titan
Form 424B5 Inovio Pharmaceuticals Inc For: 30 July By Investing.com - Investing.com UK
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Stock Falls 21% After Hours: Here's What's Going On - Benzinga
Inovio prices $20M stock offering, its second raise in quick succession - Dealroom
Inovio prices $20 million public offering of stock and warrants By Investing.com - Investing.com South Africa
Inovio Announces Pricing of $20.0 Million Pub - moomoo.com
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):